Halozyme is transforming from a royalty-based business focused on ENHANZE technology into a broader subcutaneous drug delivery platform. The company reported a 52% increase in royalty revenue for fiscal year 2025, reaching $867.8 million, and projects 30-35% royalty growth with adjusted EBITDA between $1.125 billion and $1.205 billion for 2026. Recent acquisitions and partnerships with companies like Vertex and Takeda enhance its intellectual property and position Halozyme as a comprehensive biologic delivery solutions provider. Despite strong growth and high margins, Halozyme trades at a notable valuation discount, suggesting potential investment value.
The global aerospace materials market is projected to grow from $60.38 billion in 2026 to $89.58 billion by 2031, at a CAGR of 8.21%. Growth is fueled by rising demand for lightweight composite materials that improve fuel efficiency, increased satell...
State Street Global Advisors & Affiliates disclosed a sale of 1,250 ordinary shares of DCC plc on May 22, 2026, at a price of €61.55 per share. Following this transaction, their total holding in DCC plc stands at 1,189,951 shares, representing 1.3929...
NevGold Corp. reported that all 17 drillholes at its Limousine Butte project in Nevada returned consistent oxide antimony and gold mineralization, with notable grades such as 0.32% antimony over 14.9 meters. This brownfield site contains historic cru...
TransMedics saw its stock drop nearly 50% in 2026 after missing Q1 earnings estimates despite 21% revenue growth to $174 million, driven by strong liver segment sales. Higher costs squeezed margins and net income, but management maintains 2026 revenu...
Bitcoin peaked at $126,000 in October 2025 but fell sharply due to a tech stock selloff, leveraged position liquidations, and over $3 billion in ETF outflows by January 2026. The price dropped below $60,000 in early 2026 but has since recovered to ar...
